Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals | Small Cap
Health Score : 7.54Astrazeneca Pharma India Ltd demonstrates a mixed financial performance. The company shows strong solvency, growth, and financial metrics, indicating a stable financial structure and good earnings potential. Profitability is also a strength, supported by healthy gross profit margins and returns on capital. However, efficiency ratios indicate challenges in managing inventory. Liquidity appears to be an area needing attention. Revenue and operating profit have shown good growth, but earnings per share have declined. Overall, Astrazeneca Pharma India Ltd presents a picture of a financially stable company with significant growth potential, but attention is needed to improve operational efficiency and liquidity.
Health Score : 7.54Astrazeneca Pharma India Ltd demonstrates a mixed financial performance. The company shows strong solvency, growth, and financial metrics, indicating a stable financial structure and good earnings potential. Profitability is also a strength, supported by healthy gross profit margins and returns on capital. However, efficiency ratios indicate challenges in managing inventory. Liquidity appears to be an area needing attention. Revenue and operating profit have shown good growth, but earnings per share have declined. Overall, Astrazeneca Pharma India Ltd presents a picture of a financially stable company with significant growth potential, but attention is needed to improve operational efficiency and liquidity.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
111.78
Industry Median
19.41
Small Cap Median
18.08
P/E RATIO
192.31
P/B RATIO
27.82
Industry Median
1.98
Small Cap Median
2.03
P/S RATIO
12.97
Industry Median
2.06
Small Cap Median
1.64
Others
PEG RATIO
9.91
EV/EBITDA RATIO
111.14
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹8904 as on Feb 20, 2026.
Growth Score : 8.00The company exhibits strong growth in revenue, operating profit, asset base, and net income, suggesting successful business strategies and market positioning. However, the negative earnings per share growth indicates a potential area of concern that may need further examination to ensure sustainable profitability.
Revenue Growth RateExcellentOperating Profit Growth RateExcellent
Earnings Per Share (EPS) GrowthPoorAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | -0.98 | 24.44 | 29.21 | 32.41 | 32.63 |
| Operating Profit Growth Rate | -36.3 | 91.86 | 11.52 | 38.04 | 3.15 |
| Earnings Per Share (EPS) Growth | -33.98 | 61.2 | 62.64 | -28.33 | 62.01 |
| Asset Growth Rate | 10.58 | 14.94 | 9.44 | 40.82 | 31.03 |
| Net Income Growth Rate | -33.33 | 59.68 | 63.64 | -28.4 | 62.07 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Astrazeneca Pharma India Ltd | 7.54 | 192.31 | Neutral | 230.00 | 67.85 | 170.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
AstraZeneca Pharma India Ltd. is a leading pharmaceutical company in India, part of the global AstraZeneca Group. It focuses on the discovery, development, manufacturing, and marketing of prescription medicines. The company primarily operates in key therapeutic areas such as oncology, cardiovascular, renal & metabolism, respiratory, and immunology, addressing significant healthcare needs in the Indian market.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Astrazeneca Pharma India Ltd's P/E ratio (TTM) is 111.78, compared to the industry median of 19.41 and large cap median of 18.08.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Astrazeneca Pharma India Ltd's P/B ratio is 27.82, compared to the industry median of 1.98 and large cap median of 2.03.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Astrazeneca Pharma India Ltd's P/S ratio is 12.97, compared to the industry median of 2.06 and large cap median of 1.64.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Astrazeneca Pharma India Ltd's PEG ratio is 9.91.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Astrazeneca Pharma India Ltd's EV/EBITDA ratio is 111.14.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Astrazeneca Pharma India Ltd's ROE is 21.53%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Astrazeneca Pharma India Ltd's ROA is 13.17%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Astrazeneca Pharma India Ltd's ROCE is 29%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Astrazeneca Pharma India Ltd's operating margin is 11.51%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Astrazeneca Pharma India Ltd's net margin is 8.26%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Astrazeneca Pharma India Ltd's current ratio is 1.86.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Astrazeneca Pharma India Ltd's debt-to-equity ratio is 0.12.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Astrazeneca Pharma India Ltd's interest coverage ratio is 64.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Astrazeneca Pharma India Ltd's DPS is ₹36.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Astrazeneca Pharma India Ltd's EPS is 62.01.
(Source line: "Ratios as of 11 Oct 2026, based on last traded price of ₹8904. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1979 (as Zeneca Pharma India Ltd (following demerger from ICI India Ltd.))
Headquarters: Bengaluru, Karnataka
Core Offerings: Oncology, Cardiovascular-Renal-Metabolism, Respiratory & Immunology, Neuroscience
Stock Listing: NSE (ASTRAZEN), BSE (506820)
Promoter: AstraZeneca AB (Sweden)
Incorporated in 1979 as part of ICI India Limited. In 1994, it was demerged as Zeneca Pharma India Ltd, following the global separation of ICI's pharmaceutical business. The company was renamed AstraZeneca Pharma India Ltd in 1999, subsequent to the global merger of Astra AB and Zeneca Group PLC. Today, it is a key player in India's pharmaceutical market, focusing on innovation in specialized therapeutic areas.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharmaceutical Products | 100% | N/A (company-level EBITDA reported) |
Oncology: Focuses on developing and commercializing medicines for various cancers, including lung, ovarian, and breast cancer, addressing high unmet medical needs.
Cardiovascular, Renal & Metabolism (CVRM): Offers therapies for chronic diseases such as heart failure, chronic kidney disease, and type 2 diabetes.
Respiratory & Immunology: Provides innovative medicines for respiratory conditions like asthma and COPD, and increasingly for immunological disorders.
Other Therapeutic Areas: Includes a portfolio of products in Neuroscience and Infectious Diseases, contributing to broader healthcare solutions.
Dr. Sanjeev Panchal, Managing Director: Leads the strategic direction and operations in India. He brings extensive experience in the pharmaceutical industry, having held various leadership roles across commercial and strategic functions both in India and internationally within AstraZeneca.
No major subsidiaries reported.
No major recent corporate actions on record.
The Astrazeneca Pharma India Ltd share price today is ₹8904 on NSE (ASTRAZEN), as of 11 Oct 2026.
As of 11 Oct 2026, Astrazeneca Pharma India Ltd share price is ₹8904, with previous close ₹8904. Today's range is ₹8904 to ₹8904. The 52-week range is ₹N/A to ₹N/A.
As of today, Astrazeneca Pharma India Ltd's market cap is ₹22,260 crore (Large Cap).
Astrazeneca Pharma India Ltd's current P/E ratio is 111.78, compared to the Pharmaceuticals & Biotechnology sector average of 32.70.
Astrazeneca Pharma India Ltd's current P/B ratio is 27.82.
Astrazeneca Pharma India Ltd's current dividend yield is 0.40%. Last dividend of ₹30.00 per share was declared on 17-Aug-2023.
Astrazeneca Pharma India Ltd's EPS (TTM) is ₹62.01.
AstraZeneca Pharma India Ltd. is a leading pharmaceutical company in India, part of the global AstraZeneca Group. It focuses on the discovery, development, manufacturing, and marketing of prescription medicines. The company primarily operates in key therapeutic areas such as oncology, cardiovascular, renal & metabolism, respiratory, and immunology, addressing significant healthcare needs in the Indian market.
Astrazeneca Pharma India Ltd is promoted by AstraZeneca AB (Sweden), holding 75% as of 11 Oct 2026.
Astrazeneca Pharma India Ltd is listed on NSE (ASTRAZEN) and BSE (506820). Its next quarterly results are expected on Late July / Early August 2024 (for Q1 FY25).
Receivables Turnover Ratio